Suri Vaishali, Das Prasenjit, Pathak Pankaj, Jain Ayushi, Sharma Mehar Chand, Borkar Sachin Anil, Suri Ashish, Gupta Deepak, Sarkar Chitra
Department of Pathology, All India Institute of Medical Sciences, New Delhi-110029, India.
Neuro Oncol. 2009 Jun;11(3):274-80. doi: 10.1215/15228517-2008-092. Epub 2008 Nov 3.
Glioblastoma multiforme (GBM) occurs rarely in children. Relatively few studies have been performed on molecular properties of pediatric GBMs. Our objective in this study was to evaluate the genetic alterations in pediatric GBM (age < or = 18 years) with special reference to p53, p16, and p27 protein expression, alterations of the epidermal growth factor receptor (EGFR), and deletion of the phosphate and tensin homolog gene (PTEN). Thirty cases of childhood GBMs reported between January 2002 and June 2007 were selected, and slides stained with hematoxylin and eosin were reviewed. Immunohistochemical staining was performed for EGFR, p53, p16, and p27, and tumor proliferation was assessed by calculating the MIB-1 labeling index (LI). Fluorescence in situ hybridization analysis was performed to evaluate for EGFR amplification and PTEN deletion. Histopathological features and MIB-1 LI were similar to adult GBMs. p53 protein expression was observed in 63%. Although EGFR protein overexpression was noted in 23% of cases, corresponding amplification of the EGFR gene was rare (5.5%). Deletion of the PTEN gene was also equally rare (5.5%). One case showed polysomy (chromosomal gains) of chromosomes 7 and 10. Loss of p16 and p27 immunoexpression was observed in 68% and 54% of cases, respectively. In pediatric de novo/primary GBMs, deletion of PTEN and EGFR amplification are rare, while p53 alterations are more frequent compared to primary adult GBMs. Frequency of loss of p16 and p27 immunoexpression is similar to their adult counterparts. This suggests that pediatric malignant gliomas are distinctly different from adult GBMs, highlighting the need for identification of molecular targets that may be adopted for future novel therapeutic strategies.
多形性胶质母细胞瘤(GBM)在儿童中很少见。针对儿童GBM分子特性的研究相对较少。本研究的目的是评估儿童GBM(年龄≤18岁)的基因改变,特别关注p53、p16和p27蛋白表达、表皮生长因子受体(EGFR)改变以及磷酸酶和张力蛋白同源基因(PTEN)缺失。选取了2002年1月至2007年6月间报道的30例儿童GBM病例,并对苏木精和伊红染色的切片进行复查。对EGFR、p53、p16和p27进行免疫组织化学染色,并通过计算MIB-1标记指数(LI)评估肿瘤增殖情况。进行荧光原位杂交分析以评估EGFR扩增和PTEN缺失。组织病理学特征和MIB-1 LI与成人GBM相似。63%的病例观察到p53蛋白表达。虽然23%的病例中注意到EGFR蛋白过表达,但EGFR基因的相应扩增很少见(5.5%)。PTEN基因缺失同样少见(5.5%)。1例显示7号和10号染色体多体性(染色体增加)。分别在68%和54%的病例中观察到p16和p27免疫表达缺失。在儿童新发/原发性GBM中,PTEN缺失和EGFR扩增很少见,而与原发性成人GBM相比,p53改变更频繁。p16和p27免疫表达缺失的频率与其成人对应情况相似。这表明儿童恶性胶质瘤与成人GBM明显不同,突出了识别可能用于未来新型治疗策略的分子靶点的必要性。